PMID- 37926996
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20240207
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 22
DP  - 2023 Jan-Dec
TI  - Docetaxel Plus Nedaplatin or Carboplatin as Second-Line Chemotherapy for Advanced 
      Lung Squamous Cell Carcinoma in Real-World Practice: A Single-Center Experience.
PG  - 15330338231206334
LID - 10.1177/15330338231206334 [doi]
LID - 15330338231206334
AB  - Although single-drug chemotherapy regimens were used as second-line chemotherapy 
      for advanced lung squamous cell carcinoma (LSCC) patients, there are still no 
      standard guidelines for second-line chemotherapy. The purpose of this study was 
      to compare the efficacy and safety of docetaxel combined with nedaplatin or 
      carboplatin in the second-line treatment of advanced LSCC patients. One hundred 
      and ninety-six LSCC patients receiving docetaxel plus nedaplatin (DN, n = 96) or 
      carboplatin (DC, n = 100) were retrospectively collected until disease 
      progression or unacceptable toxicity. The progression-free survival (PFS), 
      overall survival (OS), objective response rate (ORR), disease control rate (DCR), 
      and adverse events (AEs) were analyzed in the two groups. The ORR was 18.8% 
      versus 16.0%, and the DCR was 39.6% versus 34.0% in DN group and DC group 
      (P > .05 and P > .05), respectively. The PFS was 5.3 versus 3.8 months, and the 
      OS was 8.5 and 6.7 months in DN group and DC group (P = .013 and P = .404), 
      respectively. The rate of digestive reaction and hepatotoxicity was similar in DN 
      and DC groups, whereas more patients in DC group than in DN group suffered from 
      leucopenia (P < .05). Docetaxel combined with nedaplatin is an effective regimen 
      for advanced LSCC patients. Compared with a similar regimen with carboplatin, the 
      response rate was similar; however, nedaplatin regimen shows some superiority as 
      regards survival and some treatment side effect.
FAU - Zhong, Jian
AU  - Zhong J
AD  - Department of Thoracic Surgery, Affiliated Nanjing Brain Hospital, Nanjing 
      Medical University, Nanjing, Jiangsu, China.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - Department of Respiratory Medicine, Affiliated Nanjing Brain Hospital, Nanjing 
      Medical University, Nanjing, Jiangsu, China.
AD  - Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu, 
      China.
FAU - Li, Li
AU  - Li L
AD  - Department of Respiratory Medicine, Affiliated Nanjing Brain Hospital, Nanjing 
      Medical University, Nanjing, Jiangsu, China.
AD  - Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu, 
      China.
FAU - Xu, ChunHua
AU  - Xu C
AUID- ORCID: 0000-0001-8728-2183
AD  - Department of Respiratory Medicine, Affiliated Nanjing Brain Hospital, Nanjing 
      Medical University, Nanjing, Jiangsu, China.
AD  - Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu, 
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 15H5577CQD (Docetaxel)
RN  - BG3F62OND5 (Carboplatin)
RN  - 8UQ3W6JXAN (nedaplatin)
RN  - 0 (Taxoids)
SB  - IM
MH  - Humans
MH  - Docetaxel
MH  - Carboplatin/adverse effects
MH  - *Lung Neoplasms/pathology
MH  - Retrospective Studies
MH  - Taxoids/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - *Carcinoma, Squamous Cell/drug therapy/pathology
MH  - Lung/pathology
PMC - PMC10627028
OTO - NOTNLM
OT  - carboplatin
OT  - docetaxel
OT  - lung squamous cell carcinoma
OT  - nedaplatin
OT  - second-line chemotherapy
COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/11/06 06:41
MHDA- 2023/11/07 06:45
PMCR- 2023/11/05
CRDT- 2023/11/06 01:23
PHST- 2023/11/07 06:45 [medline]
PHST- 2023/11/06 06:41 [pubmed]
PHST- 2023/11/06 01:23 [entrez]
PHST- 2023/11/05 00:00 [pmc-release]
AID - 10.1177_15330338231206334 [pii]
AID - 10.1177/15330338231206334 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231206334. doi: 
      10.1177/15330338231206334.